PIK3CA and breast carcinoma: The association of alpelisib with fulvestrant was approved by FDA and EMA in 2019 and 2020, respectively, for the treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer in patients with a PIK3CA (the p110α subunit of PI3K) mutation [137].